



## Kubota Vision Announces Publication in Scientific Reports of Study Data for Wearable Myopia-Control Device

Seattle (November 23, 2021) — Kubota Vision Inc. (Kubota Vision), a clinical-stage specialty ophthalmology company and wholly-owned subsidiary of Kubota Pharmaceutical Holdings Co., Ltd. (Tokyo 4596), today announced the publication of a new paper in the journal *Scientific Reports*: Effect of short-term peripheral myopic defocus on ocular biometrics using Fresnel “press-on” lenses in humans. The paper was co-authored by Ryo Kubota, MD, PhD, Chairman, President and CEO of Kubota Vision, along with collaborators from the Manhattan Vision Associates / Institute for Vision Research (MVA) in New York City, and details the study results of axial length and choroidal thickness changes following short-term peripheral myopic defocus in normal adult subjects.

In this study, a total of 20 subjects enrolled and watched a full-field projected movie four meters away for four hours in the morning wearing corrected spectacle lenses for distance vision in both eyes. The right eye was peripherally defocused and tested with a Fresnel lens overlay of +3.50D with a central clear aperture of 11.5 mm (correlating to a clear central visual field of approximately 23 degrees), and the left eye was tested with no Fresnel lens overlay. Additional defocus sessions were conducted in 10 of these subjects with +5.00D of peripheral defocus in the right eye. Axial length and subfoveal choroidal thickness were measured and compared between the test (right) and control (left) eyes. The results demonstrated that short-term peripheral myopic defocus significantly inhibited axial elongation in adult humans, while no significant changes were observed in choroidal thickness.

The paper, titled “Effect of short-term peripheral myopic defocus on ocular biometrics using Fresnel ‘press-on’ lenses in humans,” is available in the online publication, *Scientific Reports*, at <https://www.nature.com/articles/s41598-021-02043-2>.

*Scientific Reports*, published by Springer Nature, is an open-access, peer-reviewed journal publishing original research from across all areas of the natural sciences, psychology, medicine, and engineering. It focuses only research that is scientifically robust, original, and of the highest quality, reviewed by its own extensive network of expert peers. In 2017, *Scientific Reports* became the largest journal in the world, overtaking PLOS ONE in the number of research articles published.\*<sup>1</sup>

Dr. Kubota stated, “We are thrilled this paper to be in *Scientific Reports* and feel that the mechanism of Kubota Glass technology is now being recognized as the world-class innovation it is. Our continuous research will provide stronger scientific evidence to support Kubota Glass technology and expand our business opportunities in many countries.”

\*1 <https://scholarlykitchen.sspnet.org/2017/04/06/scientific-reports-overtakes-plos-one-as-largest-megajournal/>

### About Kubota Glass™ Technology

Kubota Glass technology works to reduce the increase in axial length associated with myopia by using myopically-defocused images on the peripheral visual field to stimulate the retina. Peripheral myopic defocus is already in use in the US with a contact lens, “MiSight® 1 day” by CooperVision, which is U.S. Food and Drug Administration (FDA) approved to slow the progression of

myopia. Kubota Glass seeks to reduce the progression of myopia by stimulating the retina for shorter periods while maintaining high-quality central vision and not affecting daily activities.

### About Kubota Vision Inc.

Kubota Vision Inc. is a wholly-owned subsidiary of Kubota Pharmaceutical Holdings Co., Ltd. (Tokyo 4596) committed to translating innovation into a diverse portfolio of drugs and devices to preserve and restore vision for millions of people worldwide. Kubota Pharmaceutical group's development pipeline includes drug candidates for the treatment of diabetic retinopathy and Stargardt disease. The company is also developing a handheld OCT device for the monitoring of neovascular retinal diseases, to be used directly by patients, and wearable device for myopia control. <https://www.kubotavision.com/>; <https://www.kubotaholdings.co.jp/en/>

### Cautionary Statements

Certain statements contained in this press release are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 and the Private Securities Litigation Reform Act of 1995. Any statements contained in this press release that are not statements of historical fact may be deemed to be forward-looking statements. These forward-looking statements include statements regarding our expectations related to our development plans and ability to successfully develop and commercialize our product candidates and the potential efficacy, future development plans and commercial potential of our product candidates. These statements are based on current assumptions that involve risks, uncertainties and other factors that could cause the actual results, events or developments to differ materially from those expressed or implied by such forward-looking statements. These risks and uncertainties, many of which are beyond our control, include, but are not limited to: our investigational product candidates may not demonstrate the expected safety and efficacy; our pre-clinical development efforts may not yield additional product candidates; any of our or our collaborators' product candidates may fail in development, may not receive required regulatory approvals, or may be delayed to a point where they are not commercially viable; our clinical trials could be delayed; new developments in the intensely competitive ophthalmic pharmaceutical market may require changes in our clinical trial plans or limit the potential benefits of our investigational product candidates; the impact of expanded product development and clinical activities on operating expenses; adverse conditions in the general domestic and global economic markets; as well as the other risks identified in our filings with the Securities and Exchange Commission. These forward-looking statements speak only as of the date hereof and we assume no obligation to update these forward-looking statements, and readers are cautioned not to place undue reliance on such forward-looking statements. For a detailed discussion of the foregoing risks and other risk factors, please refer to our filings with the Securities and Exchange Commission, which are available on Kubota Pharmaceutical Holdings (Kubota Vision's parent company) investor relations website (<https://www.kubotaholdings.co.jp/en/ir/>) and on the SEC's website (<http://www.sec.gov>).

“Kubota Vision”, the Kubota Vision logo and “Kubota” are registered trademarks or trademarks of Kubota Vision Inc. or Kubota Pharmaceutical Holdings in various jurisdictions.

Media and Investor Relations Contact:

Press and Media Inquiries

Phone: +81-3-6550-8928

Email: [pr@kubotaholdings.co.jp](mailto:pr@kubotaholdings.co.jp)

###